TScan Therapeutics, Inc. (TCRX) — SEC Filings

Latest SEC filings for TScan Therapeutics, Inc. (TCRX), explained in plain English.

Sentiment Overview: 1 bullish, 2 bearish, 33 neutral, 2 mixed

Recent Filings (38)

• TScan Therapeutics Director Departs, Becomes Senior Advisor — 8-K · 2026-04-02T07:30:07-04:00 [neutral] Risk: low
  TScan Therapeutics, Inc. announced on March 31, 2026, the departure of Dr. Steven D. Altschuler from its Board of Directors. The company also appointed Dr. Alts
• 8-K Filing — 8-K · 2025-11-26T00:00:00.000Z [neutral]
• TScan's Losses Widen Amid Increased R&D Spend, Cash Reserves Dwindle — 10-Q · 2025-11-12T00:00:00.000Z [bearish] Risk: high
  TScan Therapeutics, Inc. (TCRX) reported a net loss of $35.71 million for the three months ended September 30, 2025, an increase from a net loss of $29.89 milli
• TScan Therapeutics Files 8-K on Exit Activities — 8-K · 2025-11-03T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. filed an 8-K on November 3, 2025, reporting on cost associated with exit or disposal activities, Regulation FD disclosure, and other ev
• TScan Therapeutics Files 8-K — 8-K · 2025-09-09T00:00:00.000Z [neutral] Risk: low
  TScan Therapeutics, Inc. filed an 8-K on September 9, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing
• TScan Therapeutics Announces Board and Executive Changes — 8-K · 2025-08-20T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. announced on August 14, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departu
• TScan's Losses Widen Amid Increased R&D, Revenue Jumps — 10-Q · 2025-08-12T00:00:00.000Z [mixed] Risk: high
  TScan Therapeutics, Inc. reported a net loss of $36.95 million for the three months ended June 30, 2025, an increase from a net loss of $31.66 million in the sa
• TScan Therapeutics Files 8-K on Shareholder Votes — 8-K · 2025-07-02T00:00:00.000Z [neutral] Risk: low
  TScan Therapeutics, Inc. filed an 8-K on July 2, 2025, reporting on matters submitted to a vote of security holders as of June 30, 2025. The filing details the
• TScan Therapeutics Files Definitive Proxy Statement — DEF 14A · 2025-05-14T00:00:00.000Z [neutral] Risk: low
  TScan Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on May 14, 2025, for its fiscal year ending December 31, 2024. The filing pertains to th
• TScan Therapeutics Files 10-Q for Q1 2025 — 10-Q · 2025-05-06T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business op
• 10-K Filing — 10-K · 2025-03-05T00:00:00.000Z [neutral]
• TScan Therapeutics Merges with Enliven Therapeutics, Renames Company — 8-K · 2024-12-26T00:00:00.000Z [neutral] Risk: medium
  On December 26, 2024, TScan Therapeutics, Inc. announced the closing of its previously disclosed merger agreement with Enliven Therapeutics, Inc. The transactio
• TScan Therapeutics Terminates Agreement, Incurs Obligation — 8-K · 2024-12-23T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. announced on December 20, 2024, the termination of a material definitive agreement and the creation of a direct financial obligation. T
• Enovis to Acquire TScan Therapeutics for $1.1B — 8-K · 2024-12-10T00:00:00.000Z [bullish] Risk: medium
  TScan Therapeutics, Inc. announced on December 9, 2024, that it has entered into a definitive agreement to be acquired by Enovis Corporation for approximately $
• TScan Therapeutics Reports Unregistered Equity Sale — 8-K · 2024-11-21T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. reported an unregistered sale of equity securities on November 15, 2024. The company, incorporated in Delaware, filed an 8-K form with
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• TScan Therapeutics Q3 2024 Update — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. reported its financial results for the period ending September 30, 2024. The company's revenue from collaborations and licenses is deta
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• TScan Therapeutics Enters Material Definitive Agreement — 8-K · 2024-11-01T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. announced on October 28, 2024, that it entered into a material definitive agreement. The filing does not provide specific details about
• SC 13G Filing — SC 13G · 2024-10-21T00:00:00.000Z [neutral]
• TScan Therapeutics Files Q2 2024 10-Q — 10-Q · 2024-08-12T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business ope
• Armata to Acquire TScan Therapeutics for $1.1B — 8-K · 2024-06-14T00:00:00.000Z [mixed] Risk: medium
  TScan Therapeutics, Inc. announced on June 12, 2024, that it has entered into a definitive agreement to be acquired by Armata Pharmaceuticals, Inc. for approxim
• TScan Therapeutics Files 10-Q, Reports Q1 2024 Results — 10-Q · 2024-05-13T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported its financial results and provided updates on its business op
• TScan Therapeutics Files 2024 Proxy Statement — DEF 14A · 2024-04-30T00:00:00.000Z [neutral] Risk: low
  TScan Therapeutics, Inc. filed its definitive proxy statement for the 2024 Annual Meeting of Stockholders, scheduled for June 12, 2024. The filing, made on Apri
• SC 13G Filing — SC 13G · 2024-04-29T00:00:00.000Z [neutral]
• Baker Bros. Advisors Amends TScan Therapeutics Stake — SC 13D/A · 2024-04-23T00:00:00.000Z [neutral] Risk: medium
  Baker Bros. Advisors LP, through its general partner Baker Bros. Advisors (GP) LLC and principals Felix J. Baker and Julian C. Baker, has amended its Schedule 1
• TScan Therapeutics Enters Material Agreement — 8-K · 2024-04-17T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. announced on April 16, 2024, that it entered into a Material Definitive Agreement. The company also reported on its Results of Operatio
• TScan Therapeutics Files 8-K Report — 8-K · 2024-04-16T00:00:00.000Z [neutral] Risk: low
  On April 16, 2024, TScan Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements, with no specific material
• TScan Therapeutics Files 2023 Annual Report Amendment — 10-K/A · 2024-04-10T00:00:00.000Z [neutral] Risk: low
  TScan Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company, incorporated in Delaware and
• TScan Therapeutics Files 8-K — 8-K · 2024-04-08T00:00:00.000Z [neutral] Risk: low
  TScan Therapeutics, Inc. filed an 8-K on April 8, 2024, to report other events and financial statements. The filing does not contain specific financial figures
• TScan Therapeutics Files 2023 10-K — 10-K · 2024-03-06T00:00:00.000Z [neutral] Risk: medium
  TScan Therapeutics, Inc. filed its 2023 10-K on March 6, 2024, reporting on its fiscal year ending December 31, 2023. The company, focused on biological product
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• GV 2017, L.P. Updates Passive Stake in TScan Therapeutics — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  GV 2017, L.P., a venture capital firm associated with Alphabet Inc., filed an amended Schedule 13G/A on February 9, 2024, indicating a change in their beneficia
• Pitango HealthTech Fund I Updates Passive Stake in TScan Therapeutics — SC 13G/A · 2024-02-08T00:00:00.000Z [neutral] Risk: low
  Pitango HealthTech Fund I, L.P. filed an amended Schedule 13G/A on February 8, 2024, updating its ownership in TScan Therapeutics, Inc. as of December 31, 2023.
• Adage Capital Slashes TScan Therapeutics Stake to Just 3 Shares — SC 13G/A · 2024-02-07T00:00:00.000Z [bearish]
  Adage Capital Partners, L.P. filed an amended SC 13G/A on February 7, 2024, indicating a significant reduction in their beneficial ownership of TScan Therapeuti
• TScan Therapeutics Names Gavin MacBeath CEO; David Southwell Becomes Executive Chair — 8-K · 2024-01-29T00:00:00.000Z [neutral]
  TScan Therapeutics, Inc. (TCRX) filed an 8-K on January 29, 2024, reporting that its President and CEO, David Southwell, will transition to a new role as Execut